|  |  |  |  |
| --- | --- | --- | --- |
| **Therapy** | **All patients** | **Vaccinated** | **Not vaccinated** |
| Interferons/Glatiramer acetate | 7/121 | 3/71 | 4/50 |
| Teriflunomide | 1/121 | 0/71 | 1/50 |
| Dimethyl fumarate | 18/121 | 9/71 | 9/50 |
| Fingolimod | 10/121 | 6/71 | 4/50 |
| Natalizumab | 24/121 | 13/71 | 11/50 |
| Rituximab | 10/121 | 4/71 | 6/50 |
| Daclizumab | 3/121 | 2/71 | 1/50 |

**Supplementary Table 1: Distribution of pre-therapy in our patient cohort**